Abbott Eyes Strong US Diabetes Growth In 2026, Diagnostics Recovery As China Headwinds Ease

CEO Robert Ford Says Over 20% US Diabetes Growth And Stabilizing China Volumes Will Underpin A Stronger 2026 Outlook.

 
• By Shubham Singh
  
Looking ahead, Abbott expects further acceleration in the US next year with the launch of the company’s dual-analyte sensor that measures both glucose and ketones. Picture Courtesy: Shutterstock

More from Business

More from Medtech Insight